Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031

Status:Enrolling by invitation
Therapuetic Areas:Hematology
Age Range:12 - Any
Start Date:June 6, 2018
End Date:December 2024

Use our guide to learn which trials are right for you!

An Open Label Extension Study of GBT440 Administered Orally to Patients With Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Open Label Extension Study of GBT440 Clinical Trial Patients with Sickle Cell Disease Who
Participated in GBT440 Clinical Trials

This international open-label extension (OLE) study will be available to eligible
participants from Study GBT440-031. The study will be conducted at approximately 100 clinical

All participants in GBT440-031 who completed 72 weeks of treatment are eligible for this
study. Depending on their Group assignment in GBT440-031, participants may be eligible for
this study prior to the completion of 72 weeks of treatment; see the GBT440-031 protocol for
additional information.

All participants (approximately 435) who have received treatment in Study GBT440-031 and who
meet the eligibility criteria for this study may be enrolled.

The objective of this open-label extension (OLE) study is to assess the effect of long-term
treatment with GBT440 in participants who have completed treatment in Study GBT440-031, using
the following parameters:

1. Hemolysis markers as measured by hematological laboratory parameters (e.g. hemoglobin,
reticulocytes and unconjugated bilirubin).

2. Frequency of sickle cell-related complications

3. Safety based upon AEs, clinical laboratory tests, physical examinations (PE) and other
clinical measures.

All participants will receive daily GBT440 treatment.

If both the 900 and 1500 mg dose are maintained for the GBT440-031 study's Main Population,
then participants will continue receiving the GBT440 dose they were randomized to in the
GBT440-031 study. Participants who received placebo in GBT440-031 will be re-randomized 1:1
to receive GBT440 900 mg or 1500 mg in this study. If one dose is selected from the Main
Population analysis, this dose may be used for all participants.

Duration of Treatment:

Participants may receive study drug as long they continue to receive clinical benefit which
outweighs risk as determined by the Investigator and/or until the participant has access to
GBT440 from an alternative source (i.e., commercialization or through a managed access

Inclusion Criteria:

- Male or female study participants with SCD who participated and received study
treatment in Study GBT440-031.

Note: Participants in GBT440-031 who discontinued study drug due to an AE, but who remained
on study may be eligible for treatment in this study provided the AE does not pose a risk
for treatment with GBT440.

- Females of child-bearing potential are required to have a negative urine pregnancy
test prior to dosing on Day 1.

- Female participants of child-bearing potential must use highly effective methods of
contraception to 30 days after the last dose of study drug. Male participants must
continue to use barrier methods of contraception to 30 days after the last dose of
study drug.

- Participant has provided written informed consent or assent (the ICF must be reviewed
and signed by each participant; in the case of pediatric participants, both the
consent of the participant's legal representative or legal guardian, and the
participant's assent must be obtained).

Exclusion Criteria:

- Female who is breast-feeding or pregnant.

- Participant withdrew consent from Study GBT440-031.

- Participant was lost to follow-up from Study GBT440-031.

- Participant requiring chronic dialysis.

- Any medical, psychological, safety, or behavioral conditions, which, in the opinion of
the Investigator, may confound safety interpretation, interfere with compliance, or
preclude informed consent.
We found this trial at
3555 NW 58th St # 800
Oklahoma City, Oklahoma 73112
(405) 447-8839
Lynn Health Science Institute Our mission is to provide clinical trials research and health services...
Oklahoma City, OK
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
Atlanta, GA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Chapel Hill, NC
Click here to add this to my saved trials
Baton Rouge, Louisiana 70808
Baton Rouge, LA
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Charleston, SC
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Indianapolis, IN
Click here to add this to my saved trials
630 W 168th St
New York, New York
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
New York, NY
Click here to add this to my saved trials
Oakland, California 94609
Oakland, CA
Click here to add this to my saved trials